AUS
NZ
UK
CA
USA
IND
Highlights
- Coles shares have risen 10.3% in 2024, reflecting its solid market presence.
- Pro Medicus is 140.9% above its 52-week low, highlighting significant growth.
- Coles currently offers a dividend yield of 3.82%, slightly above its 5-year average.
The Coles Group Ltd (ASX:COL) share price has seen a 10.3% increase since the start of 2024, underscoring its steady performance in the Australian retail market. Coles, which was founded in 1914 in Victoria, remains a key player in providing everyday essentials, from groceries to general merchandise and fuel. Formerly a part of Wesfarmers, Coles has operated as an independent company on the ASX since 2018 under the ticker ‘COL’.
Although Woolworths often takes the spotlight as its larger competitor, Coles maintains a strong foothold, controlling about 28% of the Australian grocery market. In addition to its supermarket operations, Coles has stakes in businesses like Liquorland, flybuys, Coles Express, and Vintage Cellars. Since its listing, Coles has built a reputation as a reliable dividend payer, adding value to its shareholders.
Pro Medicus Shares (ASX:PME)
Pro Medicus Limited has also drawn attention in 2024, with its share price now sitting 140.9% above its 52-week low. The company, founded in 1983, provides radiology IT software for healthcare institutions worldwide. Pro Medicus' Visage software, its flagship product, is known for allowing radiologists to access large imaging files remotely, enhancing diagnostic efficiency and improving patient outcomes.
This technological capability positions Pro Medicus as a leader in healthcare IT, particularly in the areas of radiology information systems (RIS) and Picture Archiving and Communication Systems (PACS).
Coles Share Price and Valuation
When evaluating Coles, one quick metric to consider is its dividend yield. Currently, Coles offers a yield of 3.82%, slightly above its 5-year average of 3.76%. This suggests that Coles shares are trading at a level that provides slightly more value compared to historical standards. It’s important to note, however, that fluctuations in yield can stem from either an increase in dividends or changes in the share price.
In Coles' case, the dividend has shown growth, with last year’s payment exceeding the 3-year average. This steady dividend increase enhances Coles’ appeal as a consistent performer in the Australian market.
Both Coles and Pro Medicus have demonstrated resilience and growth in 2024, offering investors opportunities to engage with companies that have solid market positions in retail and healthcare technology.
